Endo International plc: restructuring charge — Endo ceases QWO production & sales due to bruising concerns; expects $235-250M Q4 restructuring charges

Endo International plc

Ceasing Endo Aesthetics' QWO (cellulite treatment) due to market concerns about bruising and skin discoloration.
Annualized pre-tax cash savings of $50-60M; workforce reduction of ~90 positions.
Q4 2022 pre-tax restructuring charges of $235-250M, mainly non-cash asset impairment of $220-230M.
Seeking bankruptcy court approval for the decision; QWO remains FDA-approved but not commercially viable.
APHRODITE study showed modest bruising reduction but not enough to alleviate market concerns.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Endo International plc announced a restructuring with charges of approximately $235 million to $250 million affecting Endo Aesthetics’ QWO product line (approximately 90 full-time positions).

Type: restructuring
Charge: approximately $235 million to $250 million
Affected area: Endo Aesthetics’ QWO product line
Headcount: approximately 90 full-time positions

Exact text from the filing

On December 6, 2022, Endo International plc (together with its direct and indirect subsidiaries, “ Endo ” or the “ Company ”) announced that it will cease the production and sale of Endo Aesthetics’ QWO ® (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration. This decision is expected to result in annualized pre-tax cash savings of approximately $50 million to $60 million and a reduction to Endo’s global workforce of approximately 90 full-time positions. In connection with ceasing production and sales of QWO ® , Endo expects to incur total pre-tax restructuring charges of approximately $235 million to $250 million in the fourth quarter 2022.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-22-299492

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.